⚕ GalenOps field
←

SITE013-0223

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-11-17

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-11 (study day 11); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-04-22 (study day 143); relationship: Y

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-13 (study day 256); relationship: not assessed

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 267); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 288); relationship: N

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-01-05 (study day 401); relationship: not assessed

Data queries

No data queries.